Apotex Seeks Approval For Generic Ulcer Medication

Law360, New York (January 26, 2007, 12:00 AM EST) -- Seeking to market a new generic drug and avoid a patent lawsuit from GlaxoSmithKline, Apotex has asked a district court to approve its generic version of a popular anti-ulcer medication.

Apotex filed a complaint for declaratory judgment on Wednesday, asking the court to declare that its generic version of Zantac Syrup does not infringe Glaxo’s patent.

Apotex has already submitted and certified an Abbreviated New Drug Application for its drug, generically known as ranitidine hydrocholoride, to the U.S. Food and Drug Administration. Apotex said it has...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.